100,000 Shares in Alphatec Holdings, Inc. (NASDAQ:ATEC) Bought by Soviero Asset Management LP

Soviero Asset Management LP acquired a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 100,000 shares of the medical technology company's stock, valued at approximately $918,000. Soviero Asset Management LP owned about 0.07% of Alphatec as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Alphatec by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 5,968,980 shares of the medical technology company's stock worth $54,795,000 after purchasing an additional 47,797 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Alphatec by 36.5% during the fourth quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company's stock worth $45,800,000 after buying an additional 1,334,780 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Alphatec by 171.2% in the fourth quarter. Royal Bank of Canada now owns 3,185,283 shares of the medical technology company's stock valued at $29,240,000 after acquiring an additional 2,010,806 shares during the period. Nuveen Asset Management LLC boosted its position in shares of Alphatec by 78.4% in the fourth quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company's stock valued at $23,730,000 after acquiring an additional 1,136,330 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Alphatec by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 2,387,162 shares of the medical technology company's stock valued at $21,919,000 after acquiring an additional 24,283 shares in the last quarter. Institutional investors own 66.35% of the company's stock.

Analyst Ratings Changes

ATEC has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research note on Monday, April 14th. Barclays lifted their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. Wall Street Zen raised Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Needham & Company LLC restated a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research note on Friday, May 2nd. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 price objective (up from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $17.89.

Insider Activity

In other news, EVP David Sponsel sold 12,946 shares of Alphatec stock in a transaction on Monday, February 24th. The stock was sold at an average price of $10.73, for a total value of $138,910.58. Following the transaction, the executive vice president now owns 722,128 shares in the company, valued at approximately $7,748,433.44. This trade represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Patrick Miles sold 32,393 shares of Alphatec stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $10.89, for a total value of $352,759.77. Following the completion of the transaction, the chief executive officer now owns 5,940,391 shares in the company, valued at approximately $64,690,857.99. The trade was a 0.54% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 182,320 shares of company stock worth $2,136,227. Insiders own 22.80% of the company's stock.

Alphatec Price Performance

NASDAQ ATEC traded down $0.18 during midday trading on Thursday, hitting $12.48. The company had a trading volume of 898,809 shares, compared to its average volume of 2,038,201. The company has a market capitalization of $1.82 billion, a PE ratio of -9.75 and a beta of 1.06. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The firm has a 50-day moving average price of $10.99 and a 200-day moving average price of $10.50. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $13.25.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business had revenue of $169.18 million during the quarter, compared to the consensus estimate of $167.57 million. During the same quarter in the previous year, the business posted ($0.34) EPS. The company's revenue for the quarter was up 22.2% on a year-over-year basis. As a group, analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.